A Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION) - A35-009

Grants and Contracts Details

StatusActive
Effective start/end date3/6/243/6/26

Funding

  • Amylyx Pharmaceuticals Incorporated: $13,431.00